Abstract
Autism
is a highly disabling neurodevelopmental disorder characterized by
social deficits, language impairment, and repetitive behaviors.
There
are few effective biological treatments for this disorder, partly due to
the lack of translational biomarkers.
However, recent data suggest that
autism has reliable electrophysiological endophenotypes, along with
evidence that some deficits may be caused by NMDA receptor (NMDAR)
dysfunction.
Similarly, the NMDAR antagonist MK801 has been used in
behavioral animal models of autism.
Since MK801 has also been used as a
model of schizophrenia, this paper examines the independent and
overlapping ways in which MK801 recreates the electrophysiogical changes
present in both diseases.
Mouse EEG was recorded in response to
auditory stimuli after either vehicle or MK801 and the dose-response
relationship for each measure was determined.
ERP component amplitude
and latency analysis was performed along with time-frequency analysis of
gamma frequency inter-trial coherence and evoked power.
Evoked gamma
power and ITC were decreased by MK801 at the highest dose.
P1, N1
latency and gamma baseline power were increased in dose dependent
fashion following MK801.
There were no amplitude changes in P1 or N1.
MK801 caused alterations in evoked gamma activity, gamma ITC, gamma
baseline power, P1 and N1 latency similar to findings in autism.
These
data provide evidence indicating that NMDAR dysfunction may contribute
to deficits specific to autism and some that overlap with other
disorders such as schizophrenia.
Such observations could be important
for developing novel therapeutics, as electrophysiological
endophenotypes associate with functional measures and may provide early
biomarkers for efficacy in clinical trials.
Highlights
►
Low dose MK-801 creates EEG endophenotypes similar to autism ► At the
highest doses tested, these changes overlap with schizophrenia findings ►
These findings illustrate the relative amount of NMDAR dysfunction in
the two disorders
Keywords
- Autism, electrophysiology, endophenotype, animal models, NMDA receptor antagonist
- a Translational Neuroscience Program, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104
- b Bioengineering Graduate Group, University of Pennsylvania, Philadelphia, PA, 19104
- c Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104
Fuente: http://www.sciencedirect.com/science/article/pii/S0166432812004457
No hay comentarios:
Publicar un comentario